What are the possible causes of an elevated prothrombin time/international normalized ratio (PT/INR) in a patient who is taking the appropriate dose of warfarin?

Causes of Elevated PT/INR in Patients Taking Appropriate Warfarin Doses

An elevated PT/INR despite correct warfarin dosing results from either endogenous factors (disease states affecting coagulation or vitamin K metabolism), exogenous factors (drug interactions, dietary changes, herbal supplements), or genetic variations in drug metabolism—with drug interactions being the most common and clinically significant cause requiring immediate investigation. 1

Endogenous (Patient-Related) Factors

The FDA label identifies multiple disease states that can elevate PT/INR independently of warfarin dose changes 1:

Hepatic Dysfunction

• Hepatic disorders, infectious hepatitis, and jaundice impair synthesis of clotting factors and decrease warfarin metabolism, potentiating anticoagulant effects 1
• Hepatic dysfunction represents a dual mechanism: reduced production of vitamin K-dependent clotting factors AND decreased clearance of warfarin 1

Metabolic and Systemic Conditions

• Hyperthyroidism increases catabolism of vitamin K-dependent clotting factors 1
• Elevated temperature/fever can enhance warfarin effect 1
• Diarrhea and steatorrhea reduce vitamin K absorption 1
• Poor nutritional state and vitamin K deficiency from inadequate dietary intake 1
• Congestive heart failure affects hepatic metabolism 1

Hematologic Disorders

• Blood dyscrasias and conditions affecting blood elements modify hemostasis 1
• Cancer and collagen vascular disease can alter coagulation parameters 1

Genetic Factors

• CYP2C9 polymorphisms (*2 and *3 alleles) reduce warfarin metabolism, with *3 carriers requiring 37% lower doses and *2 carriers requiring 17% lower doses 1
• VKORC1 gene variations (especially -1639G>A allele) increase warfarin sensitivity, accounting for approximately 30% of dose variance 1
• Patients with these variants have approximately doubled risk of INR >3 during initial warfarin therapy 1

Exogenous (External) Factors

Drug Interactions - The Primary Culprit

Drug interactions represent the most common cause of unexpected INR elevation and occur through multiple mechanisms 2, 1:

CYP2C9 Inhibitors (Most Clinically Significant)

Antibiotics are particularly problematic 2:

• Trimethoprim/sulfamethoxazole nearly doubles bleeding risk and requires preemptive 25% warfarin dose reduction 2
• Metronidazole requires preemptive 33% warfarin dose reduction 2
• Fluoroquinolones (ciprofloxacin, levofloxacin, norfloxacin, ofloxacin) inhibit CYP1A2 and elevate INR 2, 1
• Macrolides (clarithromycin, erythromycin, azithromycin) inhibit CYP3A4 and increase warfarin effect 2, 1
• All antibiotics can alter gut microbiome vitamin K production, requiring close INR monitoring regardless of specific interaction 2

Other High-Risk Drug Classes 1:

• NSAIDs (diclofenac, naproxen, valdecoxib) through multiple mechanisms
• Antifungals (fluconazole, miconazole including topical)
• Amiodarone (potent CYP inhibitor)
• SSRIs (fluoxetine, fluvoxamine, sertraline)
• Proton pump inhibitors (omeprazole, esomeprazole, pantoprazole)
• Fibrates (fenofibrate, gemfibrozil)
• Acetaminophen at regular therapeutic doses

Recent Case Reports of Emerging Interactions

• Regorafenib (cancer chemotherapy) inhibits CYP2C9, causing marked PT/INR elevation requiring warfarin dose reduction 3
• Flutamide (prostate cancer) causes extreme, prolonged INR elevation lasting 2+ weeks after discontinuation 4
• Baloxavir marboxil (influenza) may compete for protein-binding sites, elevating INR 5

Critical Timing Consideration

The sequence of drug initiation matters 2:

• When warfarin is started in the presence of a CYP2C9 inhibitor, supratherapeutic INR may be avoided due to frequent monitoring during initiation
• When a CYP2C9 inhibitor is added to stable warfarin therapy, INR elevation is more likely if the interaction goes unrecognized

Enzyme Inducers Causing Paradoxical Effects

Discontinuation of CYP inducers can elevate INR 2, 6:

• Nafcillin, flucloxacillin, cloxacillin (anti-staphylococcal penicillins) induce CYP3A4/2C9 over 2-4 weeks 2
• Rifampin is a potent inducer 2
• Bosentan induces CYP2C9/3A4; switching to macitentan removes induction, causing INR >7 in one case 6
• When these drugs are stopped, warfarin dose must be reduced to prevent dangerous INR elevation

Dietary Factors

• Dietary deficiencies and reduced vitamin K intake from poor appetite or illness 1
• Prolonged hot weather affecting vitamin K status 1
• Acute illness with anorexia and vomiting reducing vitamin K intake 6

Herbal/Botanical Supplements

High-risk botanicals that INCREASE warfarin effect 1:

• Dong quai (Angelica sinensis), danshen, garlic, Ginkgo biloba, ginseng, cranberry products are most commonly associated with INR elevation 1
• Bromelains also increase warfarin effects 1
• Many botanicals contain coumarins, have antiplatelet properties, or possess fibrinolytic effects that are additive to warfarin 1

Laboratory/Technical Factors

False PT/INR Elevation

• Daptomycin can cause false INR prolongation through drug-laboratory reagent interaction, not true anticoagulation 7
• Unreliable PT/INR determinations from technical/reagent issues 1
• Thromboelastography (TEG) can distinguish true coagulopathy from laboratory artifact 7

Clinical Approach Algorithm

When encountering elevated INR on stable warfarin 2, 1:

1. Immediately review ALL medications started, stopped, or changed in the past 2-4 weeks (including over-the-counter drugs and supplements)
2. Assess for acute illness (fever, diarrhea, decreased oral intake, infection requiring antibiotics)
3. Evaluate for hepatic decompensation or new thyroid dysfunction
4. Question dietary changes or use of herbal products
5. Consider genetic testing (CYP2C9 and VKORC1) if recurrent unexplained INR variability occurs, particularly in Asian patients who may require lower doses 1
6. Verify laboratory accuracy if clinical picture doesn't match, especially with certain antibiotics like daptomycin 7

Critical Pitfall to Avoid

Never assume the warfarin dose is "correct" simply because it was previously stable—the dynamic nature of drug interactions, illness, and dietary changes means "correct" dosing is a moving target requiring continuous reassessment and more frequent INR monitoring whenever ANY change occurs in the patient's clinical status or medication regimen 2, 1.